Samah Algharib | Immunotherapy | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Samah Algharib — Mississippi State University, United States

Samah Algharib
Affiliation Mississippi State University
Country United States
Scopus ID 57211476541
Documents 42
Citations 1,190
h-index 17
Subject Area Immunotherapy
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3336-2855

Samah Algharib is affiliated with Mississippi State University and works within the broad research area of immunotherapy. The documented research record includes studies addressing antibacterial treatment strategies and veterinary infectious disease, including responsive nanogels, controlled-release hydrogels, and diagnostic perspectives related to bovine mastitis. [1] [2] [3]

Abstract

Samah Algharib, affiliated with Mississippi State University, is associated with research spanning immunotherapy, antibacterial treatment strategies, drug delivery, and veterinary infectious disease. The documented publication record includes investigations of pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, slow-release florfenicol hydrogels for intestinal bacterial infections, and contemporary approaches to bovine mastitis diagnosis. These studies collectively address therapeutic delivery, antimicrobial effectiveness, controlled release, and disease identification. The supplied research profile records 42 documents, 1,190 citations, and an h-index of 17, providing bibliometric context for the recognition of research activity in pharmaceutical and biomedical applications. [1] [2] [3]

Keywords

Immunotherapy; antibacterial therapy; florfenicol; nanogels; hydrogels; controlled drug release; Staphylococcus aureus; bovine mastitis; veterinary medicine; pharmaceutical research.

Introduction

Research associated with Samah Algharib addresses biomedical and pharmaceutical questions involving antimicrobial treatment and disease management. Published work examines responsive florfenicol nanogels and hydrogels designed to improve therapeutic delivery, while related veterinary research considers contemporary diagnostic approaches for bovine mastitis. These topics connect pharmaceutical formulation with infectious-disease applications. [1] [2] [3]

Research Profile

The supplied profile identifies immunotherapy as the principal subject area, alongside research themes involving antimicrobial agents, drug-delivery systems, bacterial infections, and veterinary health. The publications demonstrate attention to formulation characteristics, release behavior, antibacterial activity, and diagnostic considerations, providing a multidisciplinary context for pharmaceutical and biomedical investigation. [1] [2] [3]

Research Contributions

The documented studies contribute to research on responsive and controlled antimicrobial delivery. One study investigates pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, while another examines slow-release florfenicol hydrogels for intestinal bacterial infections. Related work reviews concepts and advances in bovine mastitis diagnosis, connecting treatment research with disease detection. [1] [2] [3]

Publications

The supplied publication set includes research on enhanced antibacterial effects of pH/gelatinase-responsive florfenicol nanogels, manipulated slow release of florfenicol hydrogels, and basic concepts and recent advances in bovine mastitis diagnosis. These publications collectively reflect research interests spanning pharmaceutical formulation, antimicrobial intervention, controlled release, veterinary disease management, and diagnostic science. [1] [2] [3]

Research Impact

The supplied bibliometric profile records 42 documents, 1,190 citations, and an h-index of 17. These indicators provide quantitative context for the reach of the indexed research record, while the cited publications demonstrate applications in antimicrobial treatment, drug delivery, and veterinary diagnostics. Bibliometric measures should be interpreted alongside publication quality and research context. [1] [2] [3]

Award Suitability

For an Innovative Research Award, the documented work provides evidence of research involving responsive nanogels, controlled-release hydrogels, antibacterial treatment, and veterinary diagnostic perspectives. The combination of formulation-oriented pharmaceutical research and infectious-disease applications demonstrates identifiable innovation themes that can be considered alongside the supplied publication record, citation indicators, affiliation, and the specific criteria established by the awarding organization. [1] [2] [3]

Conclusion

Samah Algharib’s documented research profile encompasses immunotherapy-related interests, antimicrobial delivery, florfenicol formulations, bacterial infection treatment, and bovine mastitis diagnostics. The supplied record combines publication activity with reported citation indicators and research addressing practical biomedical and veterinary challenges. These materials provide a structured basis for academic recognition under the stated Innovative Research Award category. [1] [2] [3]

References

  1. Enhanced antibacterial effect of pH/gelatinase-responsive florfenicol nanogels against Staphylococcus aureus. (2025). PubMed.
    https://pubmed.ncbi.nlm.nih.gov/40292404/
  2. Manipulated slow release of florfenicol hydrogels for effective treatment of anti-intestinal bacterial infections. (n.d.). International Journal of Nanomedicine, Dove Medical Press.
    https://www.dovepress.com/manipulated-slow-release-of-florfenicol-hydrogels-for-effective-treatm-peer-reviewed-fulltext-article-IJN
  3. Basic concepts, recent advances, and future perspectives in the diagnosis of bovine mastitis. (2023). Journal of Veterinary Science. https://doi.org/10.4142/jvs.23147
    https://vetsci.org/DOIx.php?id=10.4142/jvs.23147

Mohamed Husseiny Elsayed | Immunotherapy | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Mohamed Husseiny Elsayed
Beckman Research Institute of City of Hope

Mohamed Husseiny Elsayed
Affiliation Beckman Research Institute of City of Hope
Country United States
Scopus ID 8580986700
Documents 65
Citations 6,388
h-index 28
Subject Area Immunotherapy
Event Name International Top Pharmaceutical Awards
ORCID 0000-0002-3470-2858

The Innovative Research Award recognizes distinguished scientific achievements that contribute to the advancement of biomedical and pharmaceutical sciences. Mohamed Husseiny Elsayed has developed a research profile characterized by sustained contributions to immunotherapy, translational oncology, and therapeutic innovation. His scholarly output has supported the understanding of immune-mediated mechanisms and their application in clinical research environments.[1]

Abstract

This article presents an academic overview of Mohamed Husseiny Elsayed and his suitability for recognition through the Innovative Research Award. The assessment is based on publication activity, citation performance, research visibility, and contributions to immunotherapy-related investigations. Available scholarly indicators demonstrate consistent engagement with impactful biomedical research and collaborative scientific advancement.[2]

Keywords

Immunotherapy, translational medicine, oncology research, biomedical innovation, pharmaceutical sciences, clinical investigation, scientific impact, therapeutic development.

Introduction

Modern biomedical research increasingly depends on interdisciplinary approaches that integrate molecular biology, immunology, and clinical sciences. Researchers working in these domains contribute to the development of therapeutic strategies designed to address complex diseases. Mohamed Husseiny Elsayed has participated in this evolving scientific landscape through research efforts focused on immunotherapeutic applications and translational outcomes.[3]

Research Profile

The researcher is affiliated with the Beckman Research Institute of City of Hope in the United States. Bibliometric indicators report 65 indexed documents, more than 6,300 citations, and an h-index of 28. These metrics suggest sustained scholarly engagement and measurable visibility within the scientific community, particularly in immunotherapy-related disciplines.[1]

Research Contributions

Research contributions attributed to Mohamed Husseiny Elsayed include studies exploring immune responses, cancer therapeutics, and translational research methodologies. His collaborative publications have supported scientific understanding of treatment optimization and biological mechanisms relevant to disease management. Such work aligns with contemporary priorities in precision medicine and advanced therapeutic development.[4]

Publications

The publication record of Mohamed Husseiny Elsayed includes 65 scholarly documents in immunotherapy and translational oncology, reflecting sustained research productivity, scientific collaboration, and contributions to advancing biomedical knowledge and therapeutic innovation.[4]

Research Impact

Citation activity represents one indicator of scientific influence and knowledge dissemination. With thousands of citations recorded across indexed publications, the researcher demonstrates meaningful engagement from the academic community. The observed citation profile suggests that published findings have contributed to ongoing discussions and developments within biomedical research fields.[3]

Award Suitability

Evaluation for the Innovative Research Award considers originality, scholarly productivity, scientific influence, and relevance to advancing healthcare knowledge. Based on available academic indicators, Mohamed Husseiny Elsayed demonstrates characteristics commonly associated with recognized research excellence. His publication record, citation performance, and institutional affiliation collectively support consideration within competitive academic recognition programs.[2]

Conclusion

The academic profile presented in this article highlights measurable research activity and scholarly engagement within the field of immunotherapy. Bibliometric indicators, institutional affiliation, and documented scientific contributions collectively illustrate an established research trajectory. These characteristics provide a foundation for recognition within academic and professional award frameworks dedicated to scientific innovation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Mohamed Husseiny Elsayed, Author ID 8580986700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=8580986700
  2. ORCID. (n.d.). Researcher Profile: Mohamed Husseiny Elsayed.
    https://orcid.org/0000-0002-3470-2858
  3. Cobb, J., Rawson, J., Gonzalez, N., Kandeel, F., & Husseiny, M. I. (n.d.). Oral tolerogenic vaccine combined with gastrin restores immune tolerance and beta-cell function in NOD mice with type 1 diabetes.
    https://pubmed.ncbi.nlm.nih.gov/41635853/
  4. Singer, M., Hamdy, R., Ghonaim, J.H., & Husseiny, M.I. Metabolic Imbalance in Immune Cells in Relation to Metabolic Disorders, Cancer, and Infections.
    https://link.springer.com/chapter/10.1007/978-981-96-1305-2_9

Yannis Hamidou | Immunotherapy |

Published on by Top Pharmaceutical

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Denise Faustman | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Denise Faustman | Immunotherapy | Best Researcher Award

Associate Professor of Medicine at Harvard Medical School  | United States

Dr. Denise Faustman is a physician-scientist recognized for her pioneering work in immunology, autoimmunity, and type 1 diabetes research. She serves as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Her career bridges clinical medicine, molecular biology, and translational research, with a focus on advancing novel therapies for autoimmune diseases. Dr. Faustman has significantly contributed to understanding immune tolerance, vaccine-based interventions, and the role of BCG vaccination in autoimmune modulation. She is widely respected for her leadership, scientific advisory roles, and commitment to women’s health and immunological innovation.

Publication Profile 

Scopus

Education

Dr. Denise Faustman earned a B.S. in Zoology and Chemistry from the University of Michigan, followed by an M.D. and Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in St. Louis. She completed her postdoctoral training in transplantation immunology at Washington University before pursuing clinical training in internal medicine and endocrinology at Massachusetts General Hospital and Harvard Medical School. Her combined training in medicine, molecular biology, and immunology has uniquely positioned her to integrate clinical insights with advanced laboratory science, fueling her translational research on autoimmunity, immunotherapy, and novel strategies for the treatment of chronic diseases.

Experience 

Dr. Denise Faustman has built a distinguished career at Harvard Medical School and Massachusetts General Hospital, where she directs the Immunobiology Laboratory. Her academic roles span from Instructor to Associate Professor of Medicine, combined with leadership in clinical and translational immunology. She has served on numerous national and international scientific committees, including advisory roles at the FDA, NIH, NAS, and Institute of Medicine. As a physician-scientist, she bridges patient care with laboratory innovation, advancing novel treatments for autoimmune diseases. She has also provided scientific leadership for biotech companies, foundations, and research councils, shaping biomedical policy, discovery, and translational impact.

Awards and Honors 

Dr. Denise Faustman contributions have been recognized through prestigious appointments and leadership roles. She has served as Chair and Board Member of the Society for Women’s Health Research, Advisory Committee Member for the FDA, and Chair of national immunology and autoimmunity symposia. She has been elected to scientific advisory boards for biotechnology companies and foundations worldwide, including Sjögren’s Syndrome Foundation and Farallone Therapeutics. Her expertise has been sought by NASA, NIH, and the Department of Defense for defining priorities in immunology, vaccine safety, and women’s health. These roles reflect her influence, innovation, and leadership in advancing immunological and biomedical sciences.

Research Focus 

Dr. Denise Faustman research centers on autoimmunity, immune regulation, and translational immunotherapy. Her laboratory is internationally recognized for pioneering studies on immune tolerance and the use of BCG vaccine as a potential therapy for type 1 diabetes. She investigates mechanisms of T cell regulation, biomarkers for autoimmune progression, and pathways of immune modulation to translate discoveries into clinical applications. Her work bridges fundamental immunology with patient-centered research, aiming to develop safe, effective, and durable treatments for chronic autoimmune diseases. By integrating laboratory science, clinical trials, and translational medicine, Dr. Faustman is shaping innovative therapeutic strategies with global health impact.

Publication Top Notes

The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG

Late in the US pandemic, multi-dose BCG vaccines protect against COVID-19 and infectious diseases

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Association of BCG Vaccine Treatment with Death and Dementia in Patients with Non-Muscle-Invasive Bladder Cancer

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells

Letter to the Editor Regarding “The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result”

The benefits of clustering in TNF receptor superfamily signaling

Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies

BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation